These two are chemically related, act on the same receptor family, and are frequently discussed as interchangeable options for the same effect. On this site's two locked axes they are further apart than any other pair. One is an approved medicine with a fixed dose, a hard usage cap and a documented side-effect profile. The other was abandoned in development, and the reason it was abandoned is the part people skip.
| PT-141 | Melanotan 2 | |
|---|---|---|
| Evidence tier | ApprovedFDA-approved for at least one specific indication. Approval is for THAT indication only - it says nothing about the uses discussed in community protocols. | Preclinical onlyAnimal or mechanistic data plus community convention. No meaningful human evidence for the use discussed. |
| Regulatory status | FDA-approved | Not approved anywhere |
| Researched for | A melanocortin agonist working through the nervous system rather than blood flow. FDA-approved as Vyleesi. | A melanocortin agonist that signals the skin to produce more melanin from less UV exposure. |
| What people use it for | A clear increase in sexual desire and arousal in both men and women, often beginning within 45–90 minutes and lasting several hours. | Rapid tanning with less UV exposure; increased libido and arousal; mild appetite suppression alongside skin-darkening effects. |
| Reported figure | None given.The approved product specifies a single fixed 1.75 mg subcutaneous dose, capped at one per 24 hours and eight per month. | None given. |
| Route | Subcutaneous, as needed. The approval specifies a single fixed dose with hard frequency caps. | Subcutaneous by convention. No approved product or dosing schedule exists anywhere. |
| Calculator entry | No calculator entry on this site. | No calculator entry on this site. |
Scroll the table sideways →
This is the widest gap on the site between two compounds people treat as alternatives.
PT-141 is FDA-approved: “Approved as Vyleesi (bremelanotide) at a single fixed 1.75 mg subcutaneous dose, taken as needed, with a limit of one dose per 24 hours; the label separately says more than eight doses a month is not recommended. Nausea is the dominant dose-limiting side effect and is well documented in the label.” Read that carefully — the approval comes with a ceiling, not just a number. One dose per day, eight per month, and a side effect prominent enough to shape the label.
Melanotan 2 is not approved anywhere, and its entry makes a distinction that most write-ups miss: it was “genuinely abandoned in development over its side-effect profile rather than simply never studied.” That is not the same as an under-researched compound. Something was looked at, and the looking is why it stopped.
The specific concern is named: “Documented hyperpigmentation of skin and moles is the concern clinicians raise most, because it can complicate melanoma monitoring.” Darkening moles is not a cosmetic side note — it interferes with the single most common way skin cancer gets caught early.
They are related, and that relation is exactly what makes the comparison slippery: shared receptor family, overlapping reported effects on arousal, wildly different regulatory and safety records. Neither has a reconstitution calculator on this site, and neither has a reference figure published here.
Education only. This page is educational. Most compounds referenced are not approved for human use, and a "research use only" label carries no legal status of its own.
A comparison, not a recommendation. Nothing on this page ranks one compound above another or suggests running either. Where a figure appears, it is one reported reference at the reconstitution shown — not a standard, not a clinical dose.
Reference ranges. Any amounts mentioned are values commonly reported in published research and community protocols, provided for reference only. Reported does not mean established, safe, or effective.
Not medical advice. Nothing here constitutes medical advice, diagnosis, or treatment. Several of these are prescription medicines in Canada and the US, and several are approved nowhere at all. Consult a qualified healthcare professional before beginning any protocol.